Progenics Pharmaceuticals Inc PGNX Financial and Strategic SWOT Analysis Review [Report Updated: 12072017] Prices from USD $125

15:51 EDT 12 Aug 2017 | BioPortfolio Reports

Progenics Pharmaceuticals Inc PGNX Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description A detailed description of the company's operations and business divisions.
Corporate strategy Analyst's summarization of the company's business strategy.
SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.
Company history Progression of key events associated with the company.
Major products and services A list of major products, services and brands of the company.
Key competitors A list of key competitors to the company.
Key employees A list of the key executives of the company.
Executive biographies A brief summary of the executives' employment history.
Key operational heads A list of personnel heading key departments/functions.
Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
Key manufacturing facilities A list of key manufacturing facilities of the company.
Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.


Progenics Pharmaceuticals Inc Progenics is a latestage biopharmaceutical company that focuses on developing medicines and products for the treatment of cancer and related conditions. Its only commercial product, Relistor, is used for the treatment of opioidinduced constipation. The company's pipeline comprises therapeutic agents that are designed to target cancer; PSMAtargeted imaging agents for prostate cancer that enable clinicians and patients to visualize and manage their disease; and a phase III candidate for the treatment of HIV. Progenics also offers bone scan index product EXINI Bone BSI tool and is approved for use in Europe, Japan and the US. The company markets Relistor, through a licensing agreement with Salix Pharmaceuticals outside the US except Japan. Progenics is headquartered in New York, the US.

Progenics Pharmaceuticals Inc Key Recent Developments

Jun 02,2017: Progenics Pharmaceuticals Announces the Presentation of Data From Two Automated Bone Scan Index Studies at the 2017 ASCO Annual Meeting
May 04,2017: Progenics Pharmaceuticals Announces First Quarter 2017 Financial Results and Business Update
Apr 20,2017: Progenics Pharmaceuticals Announces Presentations at the 2017 American Society of Clinical Oncology ASCO Annual Meeting
Mar 09,2017: Progenics Pharmaceuticals Announces Fourth Quarter and FullYear 2016 Financial Results and Business Update
Dec 22,2016: Progenics Pharmaceuticals Announces Independent Committee's Positive Recommendation for Continuation of Phase 3 Clinical Trial of SPECT/CT Imaging Agent 1404

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Original Article: Progenics Pharmaceuticals Inc PGNX Financial and Strategic SWOT Analysis Review [Report Updated: 12072017] Prices from USD $125


More From BioPortfolio on "Progenics Pharmaceuticals Inc PGNX Financial and Strategic SWOT Analysis Review [Report Updated: 12072017] Prices from USD $125"

Quick Search

Relevant Topics

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...